MX369263B - Toxinas de clostridium degradables. - Google Patents

Toxinas de clostridium degradables.

Info

Publication number
MX369263B
MX369263B MX2015015117A MX2015015117A MX369263B MX 369263 B MX369263 B MX 369263B MX 2015015117 A MX2015015117 A MX 2015015117A MX 2015015117 A MX2015015117 A MX 2015015117A MX 369263 B MX369263 B MX 369263B
Authority
MX
Mexico
Prior art keywords
toxins
chimeras
clostridial toxins
degradable clostridial
degradable
Prior art date
Application number
MX2015015117A
Other languages
English (en)
Inventor
E Steward Lance
Ghanshani Sanjiv
Fernandez-Salas Ester
A Gilmore Marcela
Francis Joseph
Roger Aoki Kei
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX369263B publication Critical patent/MX369263B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención se refiere a toxinas de Clostridium o quimeras de toxinas de Clostridium que comprenden un sitio de inactivación de escisión, moléculas de polinucleótidos que codifican las toxinas o quimeras, composiciones que comprenden las toxinas o quimeras, y método para producir las toxinas o quimeras.
MX2015015117A 2010-05-20 2011-05-19 Toxinas de clostridium degradables. MX369263B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34657810P 2010-05-20 2010-05-20
PCT/US2011/037131 WO2011146704A1 (en) 2010-05-20 2011-05-19 Degradable clostridial toxins

Publications (1)

Publication Number Publication Date
MX369263B true MX369263B (es) 2019-11-04

Family

ID=44484018

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015117A MX369263B (es) 2010-05-20 2011-05-19 Toxinas de clostridium degradables.
MX2012013381A MX2012013381A (es) 2010-05-20 2011-05-19 Toxinas de clostridium degradables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012013381A MX2012013381A (es) 2010-05-20 2011-05-19 Toxinas de clostridium degradables.

Country Status (20)

Country Link
US (13) US8512992B2 (es)
EP (3) EP2650003B1 (es)
JP (4) JP6148979B2 (es)
KR (4) KR102321664B1 (es)
CN (1) CN103228286B (es)
AR (1) AR081407A1 (es)
AU (1) AU2011255525B2 (es)
BR (1) BR112012029666A2 (es)
CA (1) CA2799969C (es)
DK (3) DK3106170T3 (es)
ES (3) ES2596128T3 (es)
IL (1) IL223100B (es)
MX (2) MX369263B (es)
NZ (2) NZ703378A (es)
RU (1) RU2561465C2 (es)
SG (2) SG185663A1 (es)
TW (1) TWI516594B (es)
UA (1) UA108646C2 (es)
WO (1) WO2011146704A1 (es)
ZA (1) ZA201208753B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2750371B2 (ja) 1989-05-12 1998-05-13 触媒化成工業株式会社 接触分解用触媒組成物およびそれを使用した重質炭化水素油の接触分解方法
MX369263B (es) * 2010-05-20 2019-11-04 Allergan Inc Toxinas de clostridium degradables.
JP6148676B2 (ja) * 2011-11-04 2017-06-14 リポテック， エセ．ア． 活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2861732B1 (en) * 2012-05-30 2019-06-19 The University of Utah Research Foundation Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US20140170132A1 (en) 2012-12-18 2014-06-19 Allergan, Inc. Prophylatic treatment of herpes recurrence
CN104212833A (zh) * 2013-05-30 2014-12-17 江苏大学 一种新型转基因质粒载体及其构建方法、体内含新型重组基因家蚕的培育方法
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR102488220B1 (ko) 2013-09-25 2023-01-12 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
KR102466591B1 (ko) * 2014-01-31 2022-11-14 싸이톰스 테라퓨틱스, 인크. 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법
CA2947006A1 (en) 2014-04-30 2015-11-05 Eric A. Forssen Formulations of biologics for intravesical instillation
KR20220048046A (ko) 2014-07-31 2022-04-19 알러간, 인코포레이티드 방광내 주입을 위한 생물학 제형
RU2585494C2 (ru) * 2014-09-17 2016-05-27 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Рекомбинантный белок rec-mp, содержащий в своем составе последовательности миелопептидов для лечения вторичных иммунодефицитных состояний
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
HK1248737A1 (zh) 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
UA125965C2 (uk) * 2016-07-08 2022-07-20 Чілдренс Медікал Сентр Корпорейшн Новий ботулінічний нейротоксин та його похідні
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
EP3664831B1 (en) * 2017-08-11 2023-06-14 University Of Kentucky Research Foundation Anti-neurodegenerative therapeutic and use
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
SG11202105476XA (en) 2018-12-06 2021-06-29 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
KR20250122877A (ko) * 2024-02-07 2025-08-14 주식회사 알케미어 보툴리눔 독소 e형의 경쇄 변이체

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517805B1 (en) 1990-02-26 2002-07-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
DE60032367T3 (de) 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
JP4262072B2 (ja) 2003-12-05 2009-05-13 株式会社日立製作所 自動車用補助機器制御装置
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
DE602005011458D1 (de) * 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006099590A2 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AU2006339490B2 (en) * 2005-09-19 2011-12-08 Allergan, Inc. Clostridial toxin activatable clostridial toxins
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
CA2657521A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008011157A2 (en) * 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US7692222B2 (en) 2006-11-07 2010-04-06 Raytheon Company Atomic layer deposition in the formation of gate structures for III-V semiconductor
NZ585108A (en) * 2007-10-23 2012-09-28 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
MX369263B (es) * 2010-05-20 2019-11-04 Allergan Inc Toxinas de clostridium degradables.

Also Published As

Publication number Publication date
DK3106170T3 (da) 2020-07-13
RU2561465C2 (ru) 2015-08-27
US8512992B2 (en) 2013-08-20
EP3106170B1 (en) 2020-04-08
US20110287517A1 (en) 2011-11-24
KR20130054967A (ko) 2013-05-27
TWI516594B (zh) 2016-01-11
AR081407A1 (es) 2012-08-29
BR112012029666A2 (pt) 2020-10-06
JP6148979B2 (ja) 2017-06-14
UA108646C2 (xx) 2015-05-25
NZ604322A (en) 2015-01-30
EP3106170A1 (en) 2016-12-21
US9284545B2 (en) 2016-03-15
AU2011255525B2 (en) 2015-09-10
US8697414B2 (en) 2014-04-15
WO2011146704A1 (en) 2011-11-24
EP2571509A1 (en) 2013-03-27
US8685692B2 (en) 2014-04-01
US20140220627A1 (en) 2014-08-07
JP6220830B2 (ja) 2017-10-25
US20140227740A1 (en) 2014-08-14
US20180119126A1 (en) 2018-05-03
US20130196414A1 (en) 2013-08-01
US20240018500A1 (en) 2024-01-18
KR102164166B1 (ko) 2020-10-13
TW201142026A (en) 2011-12-01
ES2596128T3 (es) 2017-01-05
US20160201046A1 (en) 2016-07-14
US8697413B2 (en) 2014-04-15
ES2600463T3 (es) 2017-02-09
DK2650003T3 (da) 2016-11-28
CA2799969C (en) 2019-06-25
US20140127783A1 (en) 2014-05-08
US9297003B2 (en) 2016-03-29
CA2799969A1 (en) 2011-11-24
US9279116B2 (en) 2016-03-08
MX2012013381A (es) 2013-02-21
SG185663A1 (en) 2012-12-28
JP6467000B2 (ja) 2019-02-06
KR102321664B1 (ko) 2021-11-04
IL223100A0 (en) 2013-02-03
US8685693B2 (en) 2014-04-01
DK2571509T3 (en) 2016-10-24
KR20190010720A (ko) 2019-01-30
EP2650003A1 (en) 2013-10-16
KR20200118234A (ko) 2020-10-14
US10501731B2 (en) 2019-12-10
IL223100B (en) 2018-02-28
SG10201506567UA (en) 2015-10-29
EP2650003B1 (en) 2016-07-27
JP6644177B2 (ja) 2020-02-12
KR101942106B1 (ko) 2019-01-25
AU2011255525A1 (en) 2012-12-20
CN103228286A (zh) 2013-07-31
US20130330806A1 (en) 2013-12-12
US20130273633A1 (en) 2013-10-17
JP2015193669A (ja) 2015-11-05
JP2019088296A (ja) 2019-06-13
US20130330807A1 (en) 2013-12-12
US20130288334A1 (en) 2013-10-31
US20200190496A1 (en) 2020-06-18
US9850476B2 (en) 2017-12-26
EP2571509B1 (en) 2016-07-06
US8841111B2 (en) 2014-09-23
KR20210132753A (ko) 2021-11-04
CN103228286B (zh) 2018-01-02
JP2013529213A (ja) 2013-07-18
JP2018012696A (ja) 2018-01-25
NZ703378A (en) 2016-10-28
ZA201208753B (en) 2013-09-25
HK1180592A1 (zh) 2013-10-25
ES2813650T3 (es) 2021-03-24
RU2012154862A (ru) 2014-06-27

Similar Documents

Publication Publication Date Title
WO2011142783A3 (en) Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
NZ703378A (en) Degradable clostridial toxins
MX2016001315A (es) Variantes de enzimas.
MX2012007710A (es) Alfa-amilasas.
MX2019010453A (es) Composicion y metodos para digestion mejorada microbiana de polimeros en pozos de fractura.
BR112016012870A2 (pt) ?métodos e composições para melhorar a produção de alface
BR112012025846A2 (pt) organismo microbiano de ocorrência não natural e método para produzir etilenoglicol.
MX349576B (es) Polímeros que contienen azufre multifuncionales, composiciones de los mismos y métodos de uso.
GB201115495D0 (en) Complementary surfactant compositions and methods for making and using same
WO2010149798A3 (en) Use of polyols for enhancing the cooling effect of a cooling substance and cooling mixtures having an enhanced cooling effect
WO2009095436A3 (en) Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
MY158160A (en) Improved isoprene production using the dxp and mva pathway
MX2014001383A (es) Colageno 7 y metodos relacionados.
WO2011044279A3 (en) Microbial systems for producing commodity chemicals
BR112012027589A2 (pt) organismo microbiano de ocorrência não natural e método para produzir propileno
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
IN2012DN00939A (es)
MX379863B (es) Composiciones y metodos relacionados con una toxina mutante de clostridium difficile
MX2020002544A (es) Sales de glicopirrolato.
IN2012DN02814A (es)
MX2010005395A (es) Metodo para tratar artritis.
MX2010008555A (es) Bacteria recombinante con sistema de secrecion de hemolisina de e-coli y expresion incrementada y/o secrecion de hiya. proceso de elaboracion y usos de la misma.
IN2012DN00312A (es)
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases